Orbimed Advisors LLC Cuts Position in Natera, Inc. $NTRA

Orbimed Advisors LLC decreased its position in Natera, Inc. (NASDAQ:NTRA) by 28.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 262,000 shares of the medical research company’s stock after selling 103,800 shares during the quarter. Orbimed Advisors LLC’s holdings in Natera were worth $52,397,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC grew its holdings in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Natera in the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Natera during the 2nd quarter worth $558,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $261.99 on Monday. The company’s fifty day moving average price is $240.75 and its 200 day moving average price is $221.50. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The firm has a market capitalization of $37.52 billion, a P/E ratio of -160.73 and a beta of 1.51.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,405 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the sale, the insider directly owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 167,171 shares of company stock valued at $37,239,209 over the last ninety days. Company insiders own 5.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Canaccord Genuity Group boosted their target price on shares of Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Wolfe Research initiated coverage on Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target on the stock. Barclays dropped their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Wednesday, June 24th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Finally, Evercore restated an “outperform” rating and set a $300.00 target price on shares of Natera in a research note on Monday, July 6th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.